SRPT Q4 2021 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$201M+38.8% YoY

Gross Profit

$170M84.2% margin

Operating Income

-$106M-52.5% margin

Net Income

-$122M-60.5% margin

EPS (Diluted)

$-1.45

QoQ Revenue Growth

+6.4%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$32M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.2B

Stockholders' Equity

$928M

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$201M	$145M	+38.8%
Gross Profit	$170M	$123M	+38.3%
Operating Income	-$106M	-$171M	+38.0%
Net Income	-$122M	-$189M	+35.6%